Article

Analysts: Bausch & Lomb must work to reclaim market share

Bausch & Lomb has its work cut out as the 153-year-old company tries to re-establish its position in the contact lens-care marketplace, according to financial analysts. While the numbers have not been determined, the company anticipates that the costs associated with the ReNu with MoistureLoc product recall will "easily run" $50 to $70 million.

The company produced 75 million bottles of ReNu with MoistureLoc, with 5 million consumers worldwide, Zarella said. Since 2004, all of the company's lens kits have included 2-ounce sample bottles of the solution, helping steer consumers toward the product for future purchases, he said.

"You should think about 2006 as a rebuilding year, because that's the way I'm thinking about it," said Ron Zarella, Bausch & Lomb's chief executive officer, in a May 15 conference call with investors.

"We are committed to investing in each of our product categories-contact lenses and lens care, cataract and refractive surgery, vitreoretinal, and ophthalmic pharmaceuticals-to achieve the longer-term growth goals," Graham said. "We're confident that we have the right resources and the right people to get us back on track as we work to rebuild the lens care brand in 2006."

Cornering the market

"Clearly, what's foremost in everyone's mind right now is: What's the earnings power of the company as we look at 2007 and beyond?" said Christopher C. Cooley, CFA, a Cleveland, OH-based senior analyst for medical products/technology at FTN Midwest Securities Corp. "How much damage has this MoistureLoc issue caused to the ReNu franchise in general? Because the lens care franchise is one of the most primary drivers of their earnings growth. So the question is: How much do they have to spend to try to rebuild this business, and how much can they reclaim of their lost share?"

Alcon appears to be gaining momentum in the quest for market share with its Opti-Free line of multipurpose lens solutions, with various analyst surveys showing it now has anywhere from 60% to 78% of the market, Cooley said. Meanwhile, AMO may have gained 18% to 20% of the market, according to Cooley's survey.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.